Tirzepatide reduces motivation for fentanyl in mice (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR153.05 / JJ15; Pres time: Nov 16, 2026; 08:00 AM - 12:00 PM; Location: WCC Halls A-C; "Although medications for opioid use disorder are available, including methadone, buprenorphine, and naltrexone, many patients discontinue treatment or continue to experience craving and relapse...The effect of tirzepatide (0.01, 0.03, 0.1, and 0.3 mg/kg, i.p.) on the number of fentanyl vapor deliveries earned during these sessions was assessed under a fixed-ratio 1 (FR1) schedule of reinforcement and using a within-session behavioral economic demand procedure, in which response requirements increased hourly (FR1, 2, 4, 8, 16, 32) during a 6-hour session...Tirzepatide increased demand elasticity without affecting demand intensity, indicating reduced essential value and decreased motivation to work for fentanyl across sexes and dependence conditions. These findings identify dual GLP-1/GIP receptor agonists as a promising and readily repurposable pharmacological strategy for selectively reducing opioid motivation, supporting rapid clinical evaluation of tirzepatide..."
Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse
|
|
C. S. WILKINSON1; Z. GACSO1; F. BURTON2; H. LI3; B. J. TUNSTALL4; L. LEGGIO5; L. F. VENDRUSCOLO6
|